test

KALAMAZOO - The Apifiny blood test for prostate cancer developed by Kalamazoo-based Armune BioScience Inc. will be promoted by Quebec City, Quebec-based Aeterna Zentaris Inc. under a co-marketing agreement announced Tuesday. Apifiny is the only cancer specific, non-PSA blood test for the detection of prostate cancer. Under the co-marketing agreement, Aeterna will promote the test